{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-015851","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.245537+00:00","generated_at":"2026-05-26T07:10:15.151118+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose","bullets":["First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.","DSMB approved escalation to second cohort at 5 million receptor-positive T cells/kg of EB103 therapy.","Preliminary data showed tumor responses in all patients at Month 1; favorable safety profile.","STARLIGHT-1 is an open-label, multi-center 3+3 dose-escalation study to determine RP2D for EB103."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-015851","json":"https://secwatch.observer/filing/0001213900-25-015851.json","markdown":"https://secwatch.observer/filing/0001213900-25-015851.md","text":"https://secwatch.observer/filing/0001213900-25-015851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025015851/0001213900-25-015851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025015851/ea023173701-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T07:10:15.151118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}